SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line ...

2. 适用于由国家药品监督管理局批准的检测评估为 PD-L1 TPS ≥ 1% 的 EGFR 基因突变阴性和 ALK 阴性的局部晚期或转移性非小细胞肺癌（NSCLC）一线单药治疗； 3. 联合培美曲塞和铂类化疗适用于 EGFR 基因突变阴性和 ALK 阴性的转移性非鳞状 NSCLC 的一线治疗； 4. 联合 ...

GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...

GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...

BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America ® Holdings (LabCorp ®) (NYSE: LH) today announced the nationwide availability of a new FDA-approved diagnostic test for PD-L1 ...